{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:20:43Z","timestamp":1794374443479,"version":"4.9.0"},"reference-count":90,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,20]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Chimeric antigen receptor (CAR)-T cell therapy has achieved remarkable success in the treatment of hematological malignancies. Based on the immunomodulatory capability of CAR-T cells, efforts have turned toward exploring their potential in treating autoimmune diseases. Bibliometric analysis of 210 records from 128 academic journals published by 372 institutions in 40 countries\/regions indicates a growing number of publications on CAR-T therapy for autoimmune diseases, covering a range of subtypes such as systemic lupus erythematosus, multiple sclerosis, among others. CAR-T therapy holds promise in mitigating several shortcomings, including the indiscriminate suppression of the immune system by traditional immunosuppressants, and non-sustaining therapeutic levels of monoclonal antibodies due to inherent pharmacokinetic constraints. By persisting and proliferating <jats:italic toggle=\"yes\">in vivo<\/jats:italic>, CAR-T cells can offer a tailored and precise therapeutics. This paper reviewed preclinical experiments and clinical trials involving CAR-T and CAR-related therapies in various autoimmune diseases, incorporating innovations well-studied in the field of hematological tumors, aiming to explore a safe and effective therapeutic option for relapsed\/refractory autoimmune diseases.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003111","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T08:00:06Z","timestamp":1712995206000},"page":"1140-1150","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":30,"title":["Dawn of CAR-T cell therapy in autoimmune diseases"],"prefix":"10.1097","volume":"137","author":[{"given":"Yuxin","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"},{"name":"Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghao","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"},{"name":"Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhui","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"},{"name":"Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luoqi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"},{"name":"Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfan","family":"You","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"},{"name":"Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"},{"name":"Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"},{"name":"Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"},{"name":"Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"},{"name":"Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"},{"name":"Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"},{"name":"Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"},{"name":"Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"},{"name":"Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daishi","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"},{"name":"Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"key":"R1-20250602","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"R2-20250602","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"R3-20250602","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood.2022015789","article-title":"CAR T cells as a second-line therapy for large B-cell lymphoma: A paradigm shift?","volume":"139","author":"Westin","year":"2022","journal-title":"Blood"},{"key":"R4-20250602","article-title":"Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments","author":"Li","year":"2023","journal-title":"Chin Med J"},{"key":"R5-20250602","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/ard.2007.083162","article-title":"Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus","volume":"67","author":"Albert","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R6-20250602","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: The ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"R7-20250602","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"R8-20250602","doi-asserted-by":"crossref","first-page":"102931","DOI":"10.1016\/j.autrev.2021.102931","article-title":"Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases","volume":"21","author":"Su","year":"2022","journal-title":"Autoimmun Rev"},{"key":"R9-20250602","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease","volume":"105","author":"Afif","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R10-20250602","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/164_2019_323","article-title":"Monoclonal antibodies: Past, present and future","volume":"260","author":"Posner","year":"2019","journal-title":"Handb Exp Pharmacol"},{"key":"R11-20250602","doi-asserted-by":"crossref","first-page":"eaav1648","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"R12-20250602","first-page":"179","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"2016","author":"Ellebrecht","year":"1979","journal-title":"Science"},{"key":"R13-20250602","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/ajt.14175","article-title":"Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor","volume":"17","author":"Noyan","year":"2017","journal-title":"Am J Transplant"},{"key":"R14-20250602","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"R15-20250602","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"R16-20250602","doi-asserted-by":"crossref","first-page":"ITC81","DOI":"10.7326\/AITC202006020","article-title":"Systemic lupus erythematosus","volume":"172","author":"Kiriakidou","year":"2020","journal-title":"Ann Intern Med"},{"key":"R17-20250602","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"R18-20250602","doi-asserted-by":"crossref","first-page":"100003","DOI":"10.1016\/j.xcrm.2020.100003","article-title":"Therapeutic targeting of follicular T cells with chimeric antigen receptor-expressing natural killer cells","volume":"1","author":"Reighard","year":"2020","journal-title":"Cell Rep Med"},{"key":"R19-20250602","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"R20-20250602","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1007\/s12015-021-10251-6","article-title":"Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR","volume":"17","author":"Zhang","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"R21-20250602","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1097\/CM9.0000000000002110","article-title":"Chinese registry of rheumatoid arthritis (CREDIT) V: sex impacts rheumatoid arthritis in Chinese patients","volume":"135","author":"Jiang","year":"2022","journal-title":"Chin Med J"},{"key":"R22-20250602","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"R23-20250602","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2020-217844","article-title":"In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells","volume":"80","author":"Zhang","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R24-20250602","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4049\/jimmunol.2100643","article-title":"CD8(+) T cells expressing an HLA-DR1 chimeric antigen receptor target autoimmune CD4(+) T cells in an antigen-specific manner and inhibit the development of autoimmune arthritis","volume":"208","author":"Whittington","year":"2022","journal-title":"J Immunol"},{"key":"R25-20250602","doi-asserted-by":"crossref","first-page":"1759720X221100294","DOI":"10.1177\/1759720X221100294","article-title":"Cell-based therapies for rheumatoid arthritis: Opportunities and challenges","volume":"14","author":"Li","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R26-20250602","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jaut.2018.08.004","article-title":"Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes","volume":"96","author":"Zhang","year":"2019","journal-title":"J Autoimmun"},{"key":"R27-20250602","doi-asserted-by":"crossref","first-page":"28950","DOI":"10.1073\/pnas.2012495117","article-title":"A biomimetic five-module chimeric antigen receptor ((5M)CAR) designed to target and eliminate antigen-specific T cells","volume":"117","author":"Kobayashi","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R28-20250602","doi-asserted-by":"crossref","first-page":"104224","DOI":"10.1016\/j.cellimm.2020.104224","article-title":"Towards antigen-specific Tregs for type 1 diabetes: Construction and functional assessment of pancreatic endocrine marker, HPi2-based chimeric antigen receptor","volume":"358","author":"Radichev","year":"2020","journal-title":"Cell Immunol"},{"key":"R29-20250602","doi-asserted-by":"crossref","first-page":"102289","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J Autoimmun"},{"key":"R30-20250602","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3390\/cells12111453","article-title":"Generation of chimeric antigen receptors against tetraspanin 7","volume":"12","author":"Pieper","year":"2023","journal-title":"Cells"},{"key":"R31-20250602","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25927","article-title":"Role of B cells in multiple sclerosis and related disorders","volume":"89","author":"Comi","year":"2021","journal-title":"Ann Neurol"},{"key":"R32-20250602","doi-asserted-by":"crossref","first-page":"103341","DOI":"10.1016\/j.msard.2021.103341","article-title":"Inducing chimeric antigen receptor (CAR) regulatory T cells in-vivo: A novel concept for a potential feasible cure of demyelinating diseases","volume":"57","author":"Sedaghat","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"R33-20250602","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflammation"},{"key":"R34-20250602","doi-asserted-by":"crossref","first-page":"104222","DOI":"10.1016\/j.cellimm.2020.104222","article-title":"Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression","volume":"358","author":"De Paula Pohl","year":"2020","journal-title":"Cell Immunol"},{"key":"R35-20250602","doi-asserted-by":"crossref","first-page":"e200080","DOI":"10.1212\/NXI.0000000000200080","article-title":"CAR-T cell-mediated B-cell depletion in central nervous system autoimmunity","volume":"10","author":"Gupta","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R36-20250602","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/brain\/awab093","article-title":"Formation and immunomodulatory function of meningeal B cell aggregates in progressive CNS autoimmunity","volume":"144","author":"Mitsdoerffer","year":"2021","journal-title":"Brain"},{"key":"R37-20250602","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41582-021-00568-8","article-title":"Hope for patients with neuromyelitis optica spectrum disorders \u2013 From mechanisms to trials","volume":"17","author":"Pittock","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"R38-20250602","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: Phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R39-20250602","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"R40-20250602","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat Biotechnol"},{"key":"R41-20250602","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): A prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"key":"R42-20250602","doi-asserted-by":"crossref","first-page":"591971","DOI":"10.3389\/fimmu.2020.591971","article-title":"Milestones in personalized medicine in pemphigus and pemphigoid","volume":"11","author":"Bieber","year":"2020","journal-title":"Front Immunol"},{"key":"R43-20250602","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/1744666X.2020.1672539","article-title":"Treatment of pemphigus vulgaris: Part 2 \u2013 Emerging therapies","volume":"15","author":"Yanovsky","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"R44-20250602","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"R45-20250602","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5694\/mja17.01001","article-title":"Management of inflammatory bowel disease","volume":"209","author":"Wright","year":"2018","journal-title":"Med J Aust"},{"key":"R46-20250602","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1053\/j.gastro.2008.02.060","article-title":"Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice","volume":"134","author":"Elinav","year":"2008","journal-title":"Gastroenterology"},{"key":"R47-20250602","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1053\/j.gastro.2009.01.049","article-title":"Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor","volume":"136","author":"Elinav","year":"2009","journal-title":"Gastroenterology"},{"key":"R48-20250602","doi-asserted-by":"crossref","first-page":"102961","DOI":"10.1016\/j.jaut.2022.102961","article-title":"Flagellin-specific human CAR Tregs for immune regulation in IBD","volume":"134","author":"Boardman","year":"2023","journal-title":"J Autoimmun"},{"key":"R49-20250602","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clim.2018.04.006","article-title":"La\/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease","volume":"192","author":"Meng","year":"2018","journal-title":"Clin Immunol"},{"key":"R50-20250602","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.semarthrit.2020.09.020","article-title":"Antisynthetase syndrome \u2013 Much more than just a myopathy","volume":"51","author":"Opinc","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"R51-20250602","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"R52-20250602","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"R53-20250602","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T-cells after failure of several B cell depleting antibodies","volume":"63","author":"Taubmann","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"R54-20250602","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/jnnp-2019-321532","article-title":"Multifocal motor neuropathy: Controversies and priorities","volume":"91","author":"Yeh","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R55-20250602","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1182\/bloodadvances.2020003176","article-title":"Safety and efficacy of CAR T cells in a patient with lymphoma and a coexisting autoimmune neuropathy","volume":"4","author":"Jhaveri","year":"2020","journal-title":"Blood Adv"},{"key":"R56-20250602","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2023-224875","article-title":"CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury","author":"Lodka","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R57-20250602","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","article-title":"Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells","volume":"186","author":"Reincke","year":"2023","journal-title":"Cell"},{"key":"R58-20250602","doi-asserted-by":"crossref","first-page":"11740","DOI":"10.3390\/ijms231911740","article-title":"Cytokine storm-definition, causes, and implications","volume":"23","author":"Jarczak","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R59-20250602","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1182\/blood.2021013733","article-title":"Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients","volume":"139","author":"Qi","year":"2022","journal-title":"Blood"},{"key":"R60-20250602","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMc2213985","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Quintas-Cardama","year":"2022","journal-title":"N Engl J Med"},{"key":"R61-20250602","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"key":"R62-20250602","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/Cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R63-20250602","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"R64-20250602","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"R65-20250602","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1182\/blood-2019-130340","article-title":"A bispecific CAR-T cell therapy targeting Bcma and CD38 for relapsed\/refractory multiple myeloma: Updated results from a phase 1 dose-climbing trial","volume":"134","author":"Li","year":"2019","journal-title":"Blood"},{"key":"R66-20250602","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy-assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R67-20250602","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2022-eular.1120","article-title":"CAR-T cell treatment of refractory systemic lupus erythematosus\u2013Safety and preliminary efficacy data from the first four patients","volume":"81","author":"Schett","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R68-20250602","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"R69-20250602","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"R70-20250602","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"R71-20250602","doi-asserted-by":"crossref","first-page":"1063986","DOI":"10.3389\/fimmu.2022.1063986","article-title":"Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory\/relapsed B-cell lymphoma: Case series and review of literature","volume":"13","author":"Zhao","year":"2023","journal-title":"Front Immunol"},{"key":"R72-20250602","doi-asserted-by":"crossref","first-page":"e1900286","DOI":"10.1002\/biot.201900286","article-title":"Adeno-associated viral vectors for homology-directed generation of CAR-T cells","volume":"15","author":"Moco","year":"2020","journal-title":"Biotechnol J"},{"key":"R73-20250602","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1016\/j.cell.2022.10.026","article-title":"CAR T therapy extends its reach to autoimmune diseases","volume":"185","author":"Baker","year":"2022","journal-title":"Cell"},{"key":"R74-20250602","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"key":"R75-20250602","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"R76-20250602","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"R77-20250602","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","article-title":"Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res"},{"key":"R78-20250602","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"R79-20250602","doi-asserted-by":"crossref","first-page":"102931","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: Elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"key":"R80-20250602","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"R81-20250602","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"R82-20250602","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4049\/jimmunol.166.1.182","article-title":"Redirecting mouse CTL against colon carcinoma: Superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma","volume":"166","author":"Haynes","year":"2001","journal-title":"J Immunol"},{"key":"R83-20250602","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.cell.2020.07.018","article-title":"Multiple signaling roles of CD3\u03b5 and its application in CAR-T cell therapy","volume":"182","author":"Wu","year":"2020","journal-title":"Cell"},{"key":"R84-20250602","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc.2015.5","article-title":"NK cells and cancer: You can teach innate cells new tricks","volume":"16","author":"Morvan","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"R85-20250602","doi-asserted-by":"crossref","first-page":"100009","DOI":"10.1016\/j.xcrm.2020.100009","article-title":"CAR NK cell therapy for T follicular helper cells","volume":"1","author":"King","year":"2020","journal-title":"Cell Rep Med"},{"key":"R86-20250602","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T cells and human disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"R87-20250602","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1172\/JCI82771","article-title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","volume":"126","author":"MacDonald","year":"2016","journal-title":"J Clin Invest"},{"key":"R88-20250602","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/biomedicines10020287","article-title":"CAR-T regulatory (CAR-Treg) cells: Engineering and applications","volume":"10","author":"Arjomandnejad","year":"2022","journal-title":"Biomedicines"},{"key":"R89-20250602","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy","volume":"141","author":"Van Oekelen","year":"2023","journal-title":"Blood"},{"key":"R90-20250602","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.21.01676","article-title":"Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma","volume":"40","author":"Wang","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T19:04:42Z","timestamp":1748891082000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":90,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003111","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,12]]},"assertion":[{"value":"2023-12-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}